Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Enliven Therapeutics has received a consensus rating of "Buy" from five analysts, with an average 12-month price target of $41.20.
• Recent insider trading indicates that COO Anish Patel sold 6,667 shares, while insider Joseph P. Lyssikatos sold 12,500 shares, contributing to a total of 119,234 shares sold by insiders in the last three months.
• Enliven Therapeutics specializes in the development of cancer treatment drugs and recently reported quarterly earnings of ($0.49) earnings per share, exceeding analyst expectations.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has received a consensus rating of "Buy" from the five analysts that are presently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $41.20.

ELVN has been the topic of a number of recent analyst reports. Jones Trading dropped their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Robert W. Baird upped their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price target on the stock. Finally, HC Wainwright upped their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd.

Insider Buying and Selling

In related news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.34, for a total transaction of $135,606.78. Following the transaction, the chief operating officer directly owned 303,309 shares of the company's stock, valued at approximately $6,169,305.06. This represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $22.29, for a total value of $278,625.00. Following the transaction, the insider directly owned 952,688 shares in the company, valued at approximately $21,235,415.52. This trade represents a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 119,234 shares of company stock valued at $2,486,831. 25.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its position in shares of Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after acquiring an additional 3,490 shares in the last quarter. Duquesne Family Office LLC bought a new stake in Enliven Therapeutics during the 2nd quarter valued at approximately $9,288,000. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Enliven Therapeutics by 20.0% in the 2nd quarter. Bank of America Corp DE now owns 24,508 shares of the company's stock worth $492,000 after purchasing an additional 4,078 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in shares of Enliven Therapeutics by 150.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 59,244 shares of the company's stock worth $1,188,000 after purchasing an additional 35,582 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $20.27 on Friday. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -10.14 and a beta of 0.93. The business's 50-day moving average is $20.45 and its 200-day moving average is $19.81. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. Analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.